Traws Pharma, Inc. (TRAW) stock
TRAWNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.25−0.03 (-11.87%)
Close on Nov 13, 2026Market cap $3.86MP/E –Yield –
Traws Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Traws Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $13.36M, up 13.5% year over year. For fiscal 2025 it was $12.14M, down 5.5% from the year before. Over ten years it grew -7.3% a year on average. The highest annual figure on record is $52.76M in fiscal 2012.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.14M | -5.5% |
| FY2024 | Dec 31, 2024 | $12.85M | +12.4% |
| FY2023 | Dec 31, 2023 | $11.43M | +0.2% |
| FY2022 | Dec 31, 2022 | $11.41M | +56.3% |
| FY2021 | Dec 31, 2021 | $7.30M | -56.8% |
| FY2020 | Dec 31, 2020 | $16.90M | +8.8% |
| FY2019 | Dec 31, 2019 | $15.54M | -8.2% |
| FY2018 | Dec 31, 2018 | $16.92M | -11.5% |
| FY2017 | Dec 31, 2017 | $19.12M | -4.7% |
| FY2016 | Dec 31, 2016 | $20.07M | -22.5% |
| FY2015 | Dec 31, 2015 | $25.90M | -47.6% |
| FY2014 | Dec 31, 2014 | $49.43M | -1.5% |
| FY2013 | Dec 31, 2013 | $50.18M | -4.9% |
| FY2012 | Dec 31, 2012 | $52.76M | +133.2% |
| FY2011 | Dec 31, 2011 | $22.62M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.10M | -51.9% |
| Q1 FY2026 | Mar 31, 2026 | $4.91M | +96.0% |
| Q4 FY2025 | Dec 31, 2025 | $5.04M | +171.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.31M | -54.8% |
| Q2 FY2025 | Jun 30, 2025 | $2.29M | -42.2% |
| Q1 FY2025 | Mar 31, 2025 | $2.51M | +31.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.86M | -23.7% |
| Q3 FY2024 | Sep 30, 2024 | $5.11M | +107.8% |
| Q2 FY2024 | Jun 30, 2024 | $3.96M | +61.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.91M | -53.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.43M | -35.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.46M | -31.5% |
| Q2 FY2023 | Jun 30, 2023 | $2.46M | +20.5% |
| Q1 FY2023 | Mar 31, 2023 | $4.08M | +103.8% |
| Q4 FY2022 | Dec 31, 2022 | $3.77M | +116.2% |
| Q3 FY2022 | Sep 30, 2022 | $3.59M | +103.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.04M | +10.0% |
| Q1 FY2022 | Mar 31, 2022 | $2.00M | +3.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.75M | -61.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.76M | -58.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.85M | -61.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.94M | -42.5% |
| Q4 FY2020 | Dec 31, 2020 | $4.53M | +12.0% |
| Q3 FY2020 | Sep 30, 2020 | $4.19M | +19.1% |
| Q2 FY2020 | Jun 30, 2020 | $4.80M | +23.3% |
| Q1 FY2020 | Mar 31, 2020 | $3.37M | -17.3% |
| Q4 FY2019 | Dec 31, 2019 | $4.05M | -5.7% |
| Q3 FY2019 | Sep 30, 2019 | $3.52M | -11.6% |
| Q2 FY2019 | Jun 30, 2019 | $3.90M | -4.3% |
| Q1 FY2019 | Mar 31, 2019 | $4.08M | -11.0% |
| Q4 FY2018 | Dec 31, 2018 | $4.29M | -4.2% |
| Q3 FY2018 | Sep 30, 2018 | $3.99M | -22.5% |
| Q2 FY2018 | Jun 30, 2018 | $4.07M | -11.8% |
| Q1 FY2018 | Mar 31, 2018 | $4.58M | -6.3% |
| Q4 FY2017 | Dec 31, 2017 | $4.48M | -4.6% |
| Q3 FY2017 | Sep 30, 2017 | $5.14M | +28.8% |
| Q2 FY2017 | Jun 30, 2017 | $4.61M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.89M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.69M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.99M | – |
See a number that looks wrong?